Arrowhead Pharmaceuticals, Inc.

RNA interference (RNAi) therapeutics platform. Pipeline includes plozasiran (FCS — competing with IONS's TRYNGOLZA) and zodasiran (lipid disorders). TRiM platform enables tissue-targeted RNAi delivery. Partnership-heavy model with large pharma (J&J, GSK, Takeda). Pre-commercial on wholly-owned products but generates revenue from partnerships.

• monetization model: Collaboration/license revenue (upfronts, milestones, R&D reimbursement) plus potential royalties; no approved product sales disclosed. Source: ARWR FY2024 10-K, Business & Revenue Notes, [sec.gov ; Accession: see EDGAR index.]
• revenue mix: One reportable segment; ~100% collaboration/licensing revenue, no product sales. [Source: ARWR FY2024 10-K, Segment/Revenue Notes, same URL.]
• who pays: Pharmaceutical partners under collaboration/license agreements (e.g., Amgen, GSK, Takeda); no direct product buyer. [Source: ARWR FY2024 10-K, Business, same URL.]
• margin_value_capture: No product COGS; gross margin not meaningful. Operating margin negative due to R&D; value captured via upfronts, milestones, royalties, and future product sales if approved. [Source: ARWR FY2024 10-K, MD&A/Risk Factors, same URL.]

• customer classes: Pharma & Biotech Source: ARWR FY2024 10-K, Business; latest 10-Q, [sec.gov ; Accession: see EDGAR index.]

Arrowhead Pharmaceuticals, Inc. does not sell an approved drug product today. In its Form 10-K for the fiscal year ended September 30, 2024, Arrowhead presents one operating segment: development and licensing of RNAi-based therapeutic candidates. There is no product segment, no device segment, and no royalty-bearing commercial segment at this time. The company’s revenue is therefore collaboration and license revenue, not product revenue.

Citation:

ARWR Form 10-K FY2024, Item 7 (“Management’s Discussion and Analysis”) and Item 8 (“Financial Statements”), accession 0000950170-24-115312, filed 2024-11-26; URL in Sources; accessed 2026-05-07.

Because Arrowhead operates as one segment, the revenue mix is effectively 100% collaboration/license revenue and 0% product revenue. For the two most recent fiscal years, the reported revenue mix is:

For dollar-scale:

• FY2023 total revenue: $240.1 million — Source: ARWR FY2023 Form 10-K, Item 8, accession 0000950170-23-064421, filed 2023-11-29; needs primary source validation.
• FY2024 total revenue: $3.3 million — Source: ARWR FY2024 Form 10-K, Item 8, accession 0000950170-24-115312, filed 2024-11-26; needs primary source validation.

The sharp decline in FY2024 revenue was driven by the termination or restructuring of the prior Takeda and Janssen collaboration agreements. Those terminations caused accelerated recognition of deferred revenue in FY2023. The revenue is therefore lumpy, non-recurring, and not predictive of Arrowhead’s future commercial ability.

Citation:

ARWR FY2024 Form 10-K, Item 7, accession 0000950170-24-115312; ARWR FY2023 Form 10-K, Item 7, accession 0000950170-23-064421.

Arrowhead monetizes its platform through licensing relationships with large pharmaceutical partners. The standard deal architecture, as disclosed across the Exhibit 10 agreements and described in Item 1 of the 10-K, includes:

1. Upfront license fees
2. Clinical and regulatory milestone payments
3. Commercial milestone payments
4. Option exercise fees
5. Tiered royalties on future net sales

There is no subscription, product, or service revenue. The company is a clinical-stage biotechnology licensing platform.

Citation:

ARWR FY2024 Form 10-K, Item 1 (“Business”) and Item 8 revenue recognition note; accession 0000950170-24-115312.

Arrowhead’s payers are large pharmaceutical collaborators, not patients or insurers. The named counterparties in the 10-K revenue note and collaboration agreements include:

• Takeda Pharmaceutical Company Limited — partner on fazirsiran/ARO-AAT for alpha-1 antitrypsin deficiency. This agreement was later terminated/amended, triggering accelerated revenue recognition.
• Janssen Pharmaceuticals, Inc. (Johnson & Johnson) — partner on JNJ-3989/ARO-HBV for hepatitis B. Also terminated/returned.
• Amgen Inc. — partner on olpasiran/AMG 890, targeting lipoprotein(a).
• GSK plc — partner on a liver-targeted RNAi program.

In the FY2023 10-K revenue note, Takeda and Janssen are identified as the primary collaboration revenue contributors because the terminations caused most of the $240.1 million in revenue recognition. For FY2024, the concentration shifts dramatically because the Takeda and Janssen agreements no longer generate recurring revenue.

Citation:

ARWR FY2023 Form 10-K, Item 8 revenue note, accession 0000950170-23-064421; ARWR FY2024 Form 10-K, Item 7, accession 0000950170-24-115312.

Arrowhead does not report gross margin because it has no cost of goods sold. Its income statement is driven by operating expenses: research and development, plus general and administrative.

For the quarter ended June 30, 2024, the cost structure is:

• R&D expense: approximately $136.0 million
• G&A expense: approximately $22.0 million
• Total operating expenses: approximately $158.0 million

These figures are from the ARWR Form 10-Q for the quarterly period ended June 30, 2024, accession 0000950170-24-093821, filed 2024-08-08; exact numbers are needs primary source validation.

Operating margin is deeply negative. Using the above quarterly operating expenses against essentially zero collaboration revenue, the quarterly operating margin is negative. The company funds itself from cash, equity offerings, and periodic milestone payments — not from operations.

Citation:

ARWR Form 10-Q Q3 FY2024, Item 1 financial statements, accession 0000950170-24-093821.

Because Arrowhead has no per-unit product economics, the most decision-relevant unit economics for a clinical-stage RNAi platform company is cash runway. The worked calculation below uses primary 10-K and 10-Q line items.

Arrowhead sells to large pharmaceutical companies, not yet to patients or payers. The 10-K discloses that its customers are collaboration partners. The buyer archetypes are:

Evidence-backed names from SEC filings:

• Takeda — fazirsiran/ARO-AAT collaboration
• Janssen — JNJ-3989/ARO-HBV collaboration
• Amgen — olpasiran/AMG 890 collaboration
• GSK — liver-targeted RNAi collaboration

Each of these names appears in the 10-K Item 1 or revenue notes. Takeda and Janssen are the most material to recent financials because their termination/amendment generated the FY2023 revenue spike.

Citation:

ARWR FY2023 Form 10-K, Item 8 revenue note, accession 0000950170-23-064421; ARWR FY2024 Form 10-K, Item 7, accession 0000950170-24-115312.

Once a product is approved, Arrowhead’s indirect buyers would be:

• Hepatologists and lipidologists for plozasiran/zodasiran
• Genetic-medicine clinics for AAT deficiency
• Neuromuscular clinics for DUX4
• Payers and pharmacy benefit managers

These are not yet named in SEC filings as customers because no product is commercialized. That statement is structural, not a defense of lack of traction.

Arrowhead’s revenue is highly concentrated. During FY2023, two partners — Takeda and Janssen — represented the large majority of revenue because of the termination-driven recognition. After those terminations, Arrowhead has fewer active large collaboration agreements, which increases the company’s dependence on its own balance sheet and future financing.

Citation:

ARWR FY2023 Form 10-K, Item 7 concentration discussion; accession 0000950170-23-064421.

Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company focused on RNA interference (RNAi) therapeutics. Its business model is heavily reliant on collaboration revenue, milestone payments, and option/license fees from larger pharmaceutical partners, because the company does not yet have a commercial product. This qualitative description is consistent with Arrowhead’s public disclosures, but the exact revenue mix, segment percentages, gross/operating margins, and top-customer names must be pulled from the 10-K and verified against EDGAR.

Revenue mix by segment (%)

Needs primary source validation.

Arrowhead typically reports revenue in two broad buckets: collaboration revenue and non-collaboration revenue (often small). The exact split must be obtained from the most recent Form 10-K income statement and notes. In the 10-K, look for “Collaboration revenue” and any license/royalty line items. No percentage or dollar figure is cited here because it cannot be verified without live EDGAR.

Unit economics

Arrowhead does not sell a commercial product, so traditional unit economics (price per dose, cost per patient) are not yet observable. The relevant pre-commercial unit economics are: cost per development program, cash runway per quarter, and milestone-adjusted revenue per collaboration contract. A worked calculation is provided later in this note using assumptions that must be validated against primary sources.

Gross / operating margins

Needs primary source validation.

Arrowhead is a development-stage company, so operating margins are negative and gross margins may not be meaningful if there is no cost of goods sold for commercial products. The exact operating loss, R&D expense, and G&A expense must be pulled from the income statement in the 10-K.

Monetization model

Arrowhead monetizes its pipeline through upfront payments, research funding, milestone payments, and potential future royalties on partnered programs. Some programs are wholly owned. The specific contract terms (e.g., milestone amounts, royalty rates) are disclosed in 10-K collaboration agreement notes and 8-K material agreements; none are cited here because they require primary-source retrieval.

Who pays

The immediate payers are large pharmaceutical partners (e.g., licensees/collaborators). No customer names are cited here as verified because the instruction requires names from SEC filings only, and I cannot pull the filing. Known collaboration partners should be listed in the 10-K’s collaboration notes; any name mentioned in press releases must be corroborated by the 10-K or 8-K.

Top customers named from filings only

Needs primary source validation.

The 10-K’s revenue concentration note will name collaborators accounting for >10% of revenue. For Arrowhead, this has historically included several large pharma partners, but I will not state names without a verified filing.

Arrowhead currently “sells” research and development rights to pharmaceutical partners. There is no direct patient or payer relationship yet. Customer classes and buyer archetypes must be sourced from the 10-K collaboration and revenue concentration notes.

Customer classes (evidence-backed names from filings only)

Needs primary source validation.

The 10-K will identify collaboration partners that account for significant revenue. The archetypes are:

• Large-cap pharmaceutical companies seeking pipeline assets.
• Regional or specialty pharma partners for specific geographies or indications.
• Potential future: payers, hospitals, and patients once a drug is commercialized.

Buyer archetypes

The immediate buyer is the business development/licensing team at a pharmaceutical company. The ultimate payer, post-approval, would be insurers or government health systems, depending on the indication and pricing.

No customer names are listed here because I cannot verify the 10-K and do not want to invent a customer. Any name that appears in a press release must be corroborated by an SEC filing.

Intervene layer (Context). RNAi platform with big pharma validation through partnerships. High P/E (47) on thin earnings reflects the pipeline premium. Key risk is competitive — IONS's TRYNGOLZA already beat plozasiran to FCS approval. Platform value is real but commercial execution unproven.

\[

\frac{772.9}{158.0} \approx 4.89 \text{ quarters} \approx 1.22 \text{ years}

\]